English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/156764
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Approaches and Perspectives for Development of African Swine Fever Virus Vaccines

AutorArias, Marisa; Torre, Ana de la; Dixon, Linda; Gallardo, Carmina; Jori, Ferrán; Laddomada, Alberto; Martins, Carlos; Parkhouse, R. Michael; Revilla, Yolanda; Rodríguez, Fernando; Sánchez-Vizcaíno, J. M.
Fecha de publicación7-oct-2017
EditorMultidisciplinary Digital Publishing Institute
CitaciónVaccines 5 (4): 35 (2017)
ResumenAfrican swine fever (ASF) is a complex disease of swine, caused by a large DNA virus belonging to the family Asfarviridae. The disease shows variable clinical signs, with high case fatality rates, up to 100%, in the acute forms. ASF is currently present in Africa and Europe where it circulates in different scenarios causing a high socio-economic impact. In most affected regions, control has not been effective in part due to lack of a vaccine. The availability of an effective and safe ASFV vaccines would support and enforce control–eradication strategies. Therefore, work leading to the rational development of protective ASF vaccines is a high priority. Several factors have hindered vaccine development, including the complexity of the ASF virus particle and the large number of proteins encoded by its genome. Many of these virus proteins inhibit the host’s immune system thus facilitating virus replication and persistence. We review previous work aimed at understanding ASFV–host interactions, including mechanisms of protective immunity, and approaches for vaccine development. These include live attenuated vaccines, and “subunit” vaccines, based on DNA, proteins, or virus vectors. In the shorter to medium term, live attenuated vaccines are the most promising and best positioned candidates. Gaps and future research directions are evaluated.
Versión del editorhttp://doi.org/10.3390/vaccines5040035
URIhttp://hdl.handle.net/10261/156764
Identificadoresdoi: 10.3390/vaccines5040035
Aparece en las colecciones: (CBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
vaccines-05-00035-v2.pdf739,74 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.